TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04646863

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: laser therapy
Description: performed by MLS® Laser Therapy (ASA Srl, Vicenza, Italy). It is designed to synchronize between two modules. One is emitting at 905 nm, with peak optical power = 25 W; each pulse is composed of a pulse train (single pulse width = 100 ns, maximum frequency 90 kHz). The frequency of the pulse trains varied between 1 and 2000 Hz. The other one is emitting at 808 nm in a continuous mode (power 1.1 W) or pulsed mode (pulses repetition rate 1-2000 Hz).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: The exercises were applied on a floor mat to achieve a full body workout with 10 repetitions for each exercise and rest for one minute before beginning the next exercise to avoid muscle fatigue as the following.~1. Modified Hundred~2. Modified Single Leg Stretch~3. One Leg Circle~4. Modified Scissors

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combination
Description: laser therapy + Pilates exercises
Study: NCT03259477

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: precise segmental renal arterial clamping
Description: Precise segmental renal artery clamping eliminates global renal ischemia by performing highly selective clamping of single or multiple segmental arteries.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic partial nephrectomy
Description: Laparoscopic partial nephrectomy (LPN) has been widely adopted as a minimally invasive nephron-sparing surgery for clinical T1 renal cell carcinoma(RCC).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic partial nephrectomy
Description: Laparoscopic partial nephrectomy (LPN) has been widely adopted as a minimally invasive nephron-sparing surgery for clinical T1 renal cell carcinoma(RCC).
Study: NCT02457377

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic cerclage
Description: The vesico-uterine peritoneum is opened \& the urinary bladder is dissected downwards . Both needles are passed through the lower uterine tissue medial to uterine vessels on the right \& left sides . Then, both needles are passed through the remaining cervical tissue medial to uterosacral ligaments towards the posterior vaginal fornix (on the right \& left sides) guided by laparoscopic illumination . When the needles' blunt ends pierce the vaginal vault, the assistant pull them through the posterior vaginal fornix . After trimming of both needles, the Mersilene tape is tied tightly behind the intravaginal segment of the cervix with five knots \&
Study: NCT01968993

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nanOss Bioactive - posterolateral gutter
Description: Participants will undergo instrumented PLF at one or two adjacent levels from L2-S1 with PEEK interbody cages (containing allograft or autograft) using nanOss Bioactive in combination with autograft and bone marrow aspirate in the posterolateral gutter on one side. Autograft alone will be used in the opposite posterolateral gutter.
Study: NCT04870008

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture
Description: The side of patient's scar that will receive the sutures placed at 2 or 5 mm from wound edge.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture
Description: The side of patient's scar that will receive the sutures placed at 2 or 5 mm from wound edge.
Study: NCT02712268

Intervention type: OTHER
Group type: OTHER
Intervention: Checklist
Description: Introduction of a 5-point checklist to be used by all physicians on the internal medicine wards to review and adapt the medications of the patient.
Study: NCT01208064

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: pharmacological study

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: quality-of-life assessment
Study: NCT04621409

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Liver-enriched antimicrobial peptide 2
Description: IV infusion of LEAP2, approximately 5 hours

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion of saline, approximately 5 hours
Study: NCT04357275

Intervention type: OTHER
Intervention: ICU treatment
Description: ICU treatment according to standard of care
Study: NCT01827007

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Volume expansion with gelofusine
Study: NCT01911975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: comparison between lacosamide 200mg twice daily and microcrystalline cellulose (placebo) 200mg twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: comparison between microcrystalline cellulose (placebo) 200mg twice daily and lacosamide 200mg twice daily.
Study: NCT02568384

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Onyx BG Meter / App System
Description: Subjects with diabetes used the Onyx BG Meter / App System at home and assessed software operations, ease of use of the system, and clarity and utility of user instructions.
Study: NCT01929109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered orally
Study: NCT01679821

Intervention type: OTHER
Intervention: A questionnaire and a clinical examination
Description: Seventy dental students of State University of West of Paraná - UNIOESTE, seventy patients treated at the UNIOESTE Dental Clinic that wore removable partial denture (partially edentulous) and seventy patients with double complete dentures treated in Center for Dental Specialties of Cascavel, Paraná, Brazil. Students in orthodontic treatment or with less than one year after the end of orthodontic treatment were excluded from the research. Patients wearing a complete denture in one maxillary and a removable partial denture in another maxillary, and patients wearing just one complete denture were not included in the research.

Intervention type: OTHER
Intervention: A questionnaire and a clinical examination
Description: Seventy dental students of State University of West of Paraná - UNIOESTE, seventy patients treated at the UNIOESTE Dental Clinic that wore removable partial denture (partially edentulous) and seventy patients with double complete dentures treated in Center for Dental Specialties of Cascavel, Paraná, Brazil. Students in orthodontic treatment or with less than one year after the end of orthodontic treatment were excluded from the research. Patients wearing a complete denture in one maxillary and a removable partial denture in another maxillary, and patients wearing just one complete denture were not included in the research.

Intervention type: OTHER
Intervention: A questionnaire and a clinical examination
Description: Seventy dental students of State University of West of Paraná - UNIOESTE, seventy patients treated at the UNIOESTE Dental Clinic that wore removable partial denture (partially edentulous) and seventy patients with double complete dentures treated in Center for Dental Specialties of Cascavel, Paraná, Brazil. Students in orthodontic treatment or with less than one year after the end of orthodontic treatment were excluded from the research. Patients wearing a complete denture in one maxillary and a removable partial denture in another maxillary, and patients wearing just one complete denture were not included in the research.
Study: NCT01570465

Intervention type: OTHER
Intervention: Observation
Description: Assess the impact of each type of severe infections (SI) over the 24-month overall survival of young patients with newly diagnosed acute myeloid leukemia along a predefined antileukemic treatment strategy.
Study: NCT01891292

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: 0.25-0.35 mg/kg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetylcysteine
Description: N-Acetylcysteine 0.5 mmol/kg
Study: NCT01790165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDT067 and Lamisil
Description: Topical administration of TDT067 and single oral administration of 250 mg Lamisil tablet
Study: NCT01310049

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 32731
Description: * Part 1 and 2: Oral single dose of oral solution or capsule~* Part 3: Twice daily dose of oral solution or capsule for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 32731
Description: * Part 1 and 2: Oral single dose of oral solution or capsule~* Part 3: Twice daily dose of oral solution or capsule for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 32731
Description: * Part 1 and 2: Oral single dose of oral solution or capsule~* Part 3: Twice daily dose of oral solution or capsule for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 32731
Description: * Part 1 and 2: Oral single dose of oral solution or capsule~* Part 3: Twice daily dose of oral solution or capsule for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 32731
Description: * Part 1 and 2: Oral single dose of oral solution or capsule~* Part 3: Twice daily dose of oral solution or capsule for 7 days
Study: NCT01739283

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GIP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GIP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GLP-1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Study: NCT02799602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1841788 / darolutamide (ODM-201)
Description: 600mg (2 tablets of 300 mg) of darolutamide (ODM-201)/placebo twice daily with food, equivalent to a total a daily dose of 1200 mg in addition to standard ADT (luteinizing hormone releasing hormone (LHRH) agonist/antagonist or orchiectomy) and 6 cycles of docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard ADT (androgen deprivation therapy)
Description: As prescribed by the treating physician.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard ADT (androgen deprivation therapy)
Description: As prescribed by the treating physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: As prescribed by the treating physician.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: As prescribed by the treating physician.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching darolutamide (ODM-201) tablets in appearance, bid orally with food, in addition to standard ADT (luteinizing hormone releasing hormone \[LHRH\] agonist/antagonist or orchiectomy) and 6 cycles of docetaxel.
Study: NCT00950872

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Duet TRS
Description: Patients will have their gastric pouch created with ENDO GIA staplers with Single Use Loading Units with Duet TRS.
Study: NCT00963209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study: NCT02556242

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted indoor residual spraying
Description: IRS is carried out in neighbourhoods of cases

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Generalised Indoor residual spraying
Description: IRS is carried out as normally practiced
Study: NCT04643678

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra
Description: Patient will receive Anakinra 100 mg SC injection every 12 hours for 3 days, then 100 mg once daily from day 4 to day 7 plus Standard of Care

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Patients will receive the Standard of Care therapy as per the local treatment protocol
Study: NCT00914888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tigecycline
Description: Subject with cIAI:~Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12 hours, metronidazole placebo IV will be administered every 8 hours. In addition, at the discretion of the investigator, an aminoglycoside placebo IV may also be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tigecycline
Description: Subject with CAP:~IV therapy period: Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12h. At the discretion of the investigator oral clarithromycin placebo may be given every 12h.~Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside
Description: Subject with cIAI:~Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12 hours, metronidazole 10 mg/kg (maximum of 1 g/dose) IV will be administered every 8 hours.~In addition, at the discretion of the investigator, an aminoglycoside IV (adjusted dose if necessary) may also be given.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAP: Ceftriaxone, plus if applicable oral clarithromycin
Description: Subject with CAP:~IV therapy period: Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12h. At the discretion of the investigator, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old).~Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old).
Study: NCT02281942

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Education
Study: NCT00257296

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening and Intervention
Description: Screening for intimate partner violence and providing a multi-faceted intervention which depends on the needs of the patient

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Screening for intimate partner violence and provide enhanced usual care which includes providing resource list, educating medical staff and partner violence and instructing physicians to help all patients regardless of assigned arm.
Study: NCT01798069

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: reflective writing
Description: Students allocated to the experimental arm will follow 5 sessions in Class-led instruction of reflexive writing workshops. They will be divided into 12 sub-groups of 8 students. They will write their stories about their own experiences or the experiences of their family / patient.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: reading medical publication workshops
Study: NCT02941809

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Open-Label Placebo (OLP)
Description: We are designating this as a behavioral intervention for two reasons: (1) the placebo pill is physiologically inert and is not classified under FDA regulations; and (2) other studies have demonstrated that the efficacy of the placebo pill is strongly dependent on the participants' anticipation of an effect. We are presenting the pill's efficacy in an open and transparent way to the participants, but using a positive frame. We feel that this qualifies the placebo pill use as a behavioral intervention, in the same general category as exercise or relaxation.
Study: NCT01986582

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxymetazoline
Description: Intranasal application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxymetazoline
Description: Intranasal application

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyl-propyl-methyl cellulose powder
Description: Intranasal application

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (lactose powder)
Description: Intranasal application
Study: NCT01226056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001 in combination with sorafenib
Description: Phase I / Dose escalation: during the first cycle RAD001 (2.5-10 mg/day) will be administered alone, once a day, on days 1-14 to allow PK-profiling of the drug. From day 15 sorafenib administration (400-800 mg/day) twice a day will be added.~The cycle 1 will last 6 weeks, subsequent cycles will last 4 weeks (the 2 drugs administered in combination from day 1 to day 28).~Phase II: The drugs will be administered at the Recommended Dose and each treatment cycle will last 4 weeks.
Study: NCT04811768

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary sinus augmentation
Description: The surgery was performed under local anaesthesia in both groups, lateral window preparation and window coverage was carried out based on randomization.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary sinus augmentation
Description: The surgery was performed under local anaesthesia in both groups, lateral window preparation and window coverage was carried out based on randomization.
Study: NCT02090439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silodosin
Study: NCT02795104

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Intervention via brochure
Description: Educational Intervention via brochure:~In this arm of the educational intervention the participant receives brochures

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Intervention via DVD
Description: Educational Intervention via DVD: In this arm of the educational intervention the participant receive a tailored interactive DVD to watch

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Intervention-DVD & Telephone Based Navigation
Description: Educational Intervention via Telephone-Based Navigation: In this arm of the educational intervention the participant receives a tailored interactive DVD to watch and telephone calls from a patient navigator
Study: NCT04872322

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.5% Injectable Solution
Description: Participants will receive the nerve block preoperatively using 0.5% ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.25% Injectable Solution
Description: Participants will receive the nerve block preoperatively using 0.25% ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.25% Injectable Solution
Description: Participants will receive the nerve block preoperatively using 0.25% ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Percocet Pill
Description: After surgery participants will be given a prescription for Percocet to be taken as needed for pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Percocet Pill
Description: After surgery participants will be given a prescription for Percocet to be taken as needed for pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norco Pill
Description: After surgery participants will be given a prescription for Norco to be taken as needed for pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norco Pill
Description: After surgery participants will be given a prescription for Norco to be taken as needed for pain

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Foot/Ankle Surgery
Description: Participant will undergo foot or ankle surgery and receive a popliteal nerve block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Foot/Ankle Surgery
Description: Participant will undergo foot or ankle surgery and receive a popliteal nerve block
Study: NCT02740608

Intervention type: DEVICE
Group type: OTHER
Intervention: OrganOx metra
Description: Normothermic Machine Liver Perfusion
Study: NCT01199757

Intervention type: DRUG
Intervention: Fluticasone furoate
Description: cohort of patients receiving fluticasone furate

Intervention type: DRUG
Intervention: mometasone furoate
Description: cohort receiving mometasone furoate

Intervention type: DRUG
Intervention: fluticasone propionate
Description: cohort of patients on fluticasone propionate
Study: NCT04057053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netarsudil 0.02% Ophthalmic Solution
Description: Use of Netarsudil 0.02% ophthalmic solution daily after surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Netarsudil 0.02% Ophthalmic Solution
Description: Use of Netarsudil 0.02% ophthalmic solution daily after surgery
Study: NCT00922597

Intervention type: BIOLOGICAL
Intervention: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Description: Patients undergoing surgery and receiving continuous infusion with Kogenate Bayer according to local drug information.
Study: NCT01937390

Intervention type: DRUG
Intervention: Tiotropium 2x2.5µg tiotropium (equivalent to 2x3.154µg tiotropium bromide monohydrate) Respimat® inhaler and cartridge Solution for inhalation
Description: Respimat® inhaler and cartridge Solution for inhalation

Intervention type: DRUG
Intervention: Indacterol 300 µg
Description: inhalation powder

Intervention type: DRUG
Intervention: Tiotropium 18µg (equivalent to 22.5µg tiotropium bromide monohydrate) HandiHaler® device Inhalation powder, hard capsule
Description: HandiHaler® device Inhalation powder, hard capsule

Intervention type: DRUG
Intervention: Indacterol 150 µg
Description: inhalation powder
Study: NCT00221507

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reminder-Recall-Outreach

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Case Management

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Navigator